What are the Clinical Implications of Targeting mTOR in Cancer?
Targeting the mTOR pathway holds significant promise for cancer therapy. mTOR inhibitors such as rapamycin and its analogs (rapalogs) have been developed and are in clinical use. These inhibitors can particularly benefit patients with mutations in the PI3K/AKT/mTOR pathway. However, resistance to mTOR inhibitors can occur, necessitating combination therapies with other targeted agents.
